篇名

發炎性腸道疾病的免疫生物製劑治療

並列篇名

Immunomodulators and Biologics for Inflammatory Bowel Diseases

DOI

10.6320/FJM.201807_22(4).0007

作者

魏淑鉁(Shu-Chen Wei)

關鍵字

發炎性腸道疾病 ; 免疫調節劑 ; 生物製劑 ; inflammatory bowel disease ; immunomodulators ; biologics

出版品名稱

台灣醫學

卷期/出版年月

22卷4期

頁次

405 - 410

內容語文

繁體中文

中文摘要

近來由於西化的飲食(高脂,高甜度)衝擊及環境衛生改善(減少了腸道在成人期間之前免疫系統的刺激與教育),發炎性腸道疾病的患者有日漸增多的趨勢。由潰瘍性大腸炎(ulcerative colitis)及克隆氏症(Crohn's disease)所造成的慢性腸道發炎疾病,總稱為發炎性腸道疾病(IBD),患有此種症狀的病友,需要長期的藥物控制、定期的腸鏡追蹤,近二十年來,對此疾病的致病機轉漸漸增加了解,也由此衍生新的治療,如免疫調節及生物製劑,對中重度患者,經由免疫調節及生物製劑的使用的確可促進腸道粘膜的癒合,因此改善病人的治療效果降低住院/手術,進而改善病人的生活品質。目前可使用於治療發炎性腸道疾病的生物製劑有:腫瘤壞死因子抗體,整合素抗體,介白素23抗體幾大類,經由這些生物製劑的使用,治療效果可大幅提升,但仍有許多待解決的問題(非全部病人都有效,使用一陣子之後療效降低,費用高所以健保僅給付部分時間)有待將來的研究解決,以造福更多的病患。

英文摘要

Recently, the incidence and prevalence of inflammatory bowel disease (IBD) increased as a world wide trend. It probably associated with the western style diet (high fat and sweet) as well as the improved hygiene. Ulcerative colitis (UC) and Crohn's disease (CD) are the two major forms of inflammatory bowel disease. As a chronic disease, IBD patients need long term medical treatment and regular endoscopic monitoring. In recent two decades, with the increasing understanding of the pathophysiology of IBD, novel treatment has been developed, for example, the biologics. For moderate to severe disease IBD patients, treating with immunomodulators and biologics, the treatment goal as mucosal healing could be achieved in order to decrease the admission/surgical rate, as well as to improve the life quality of the patients. Currently, there are several kinds of biologics (TNF-a antibody, Interleukin 23 antibody, and Integrin antibody). With these biologics, the treatment efficacy could increase dramatically. However, there are still unmet needs, for example, not all patients could respond to the treatment (primary failure), secondary failure (lost of response during the maintenance therapy) and high cost that not all patients could afford the lifelong use…). Further studies and government's policy modification are needed to solve these unmet needs.

主題分類 醫藥衛生 > 醫藥衛生綜合
參考文獻
  1. Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55. doi: 10.1056/NEJM200107263450403
    連結:
  2. Huang PH, Liao YH, Wei CC, et al: Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study. J Eur Acad Dermatol Venereol 2008;22:923-30. doi: 10.1111/j.1468-3083.2007.02575.x
    連結:
  3. Gordon KB, Papp KA, Hamilton TK, et al: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80. doi: 10.1001/jama.290.23.3073
    連結:
  4. Tsai TF, Liu MT, Liao YH, et al: Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study. J Eur Acad Dermatol Venereol 2008;22:345-52. doi: 10.1111/j.1468-3083.2007.02430.x
    連結:
  5. Seminara NM, Gelfand JM: Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg 2010;29:16-9. doi: 10.1016/j.sder.2010.01.001
    連結:
  6. Leonardi CL, Powers JL, Matheson RT, et al: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22. doi: 10.1056/NEJMoa030409
    連結:
  7. Menter A, Tyring SK, Gordon K, et al: Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15. doi: 10.1016/j.jaad.2007.09.010
    連結:
  8. Asahina A, Nakagawa H, Etoh T, et al: Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010;37:299-310. doi: 10.1111/j.1346-8138.2009.00748.x
    連結:
  9. Cai L, Gu J, Zheng J, et al: Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol 2017;31:89-95. doi: 10.1111/jdv.13746
    連結:
  10. Chiu HY, Wang TS, Chan CC, et al: Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis. Acta Derm Venereol 2015;95:711-6. doi: 10.2340/00015555-2069
    連結:
  11. Leonardi CL, Kimball AB, Papp KA, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. doi: 10.1016/S0140-6736(08)60725-4
    連結:
  12. Tsai TF, Ho JC, Song M, et al: Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011;63:154-63. doi: 10.1016/j.jdermsci.2011.05.005
    連結:
  13. Igarashi A, Kato T, Kato M, et al: Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012;39:242-52. doi: 10.1111/j.1346-8138.2011.01347.x
    連結:
  14. Kim BS, Lee WK, Pak K, et al: Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate to severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose positron emission tomography-computed tomography. J Am Acad Dermatol 2018;pii: S0190-9622 (18)30461-4. doi: 10.1016/j.jaad.2018.03.011
    連結:
  15. Tsai TF, Ho V, Song M, et al: The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012;167: 1145-52. doi: 10.1111/j.1365-2133.2012.11142.x
    連結:
  16. Griffiths CE, Strober BE, van de Kerkhof P, et al: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28. doi: 10.1056/NEJMoa0810652
    連結:
  17. Papp KA, Griffiths CE, Gordon K, et al: Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168:844-54. doi: 10.1111/bjd.12214
    連結:
  18. Langley RG, Elewski BE, Lebwohl M, et al: Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med 2014;371: 326-38. doi: 10.1056/NEJMoa1314258
    連結:
  19. Blauvelt A, Prinz JC, Gottlieb AB, et al: Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015;172:484-93. doi: 10.1111/bjd.13348
    連結:
  20. Lacour JP, Paul C, Jazayeri S, et al: Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol 2017;31:847-56. doi: 10.1111/jdv.14073
    連結:
  21. Blauvelt A, Reich K, Tsai TF, et al: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 2017;76:60-9. doi: 10.1016/j.jaad.2016.08.008
    連結:
  22. Wu NL, Hsu CJ, Sun FJ, Tsai TF: Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study. J Dermatol 2017;44:1129-37. doi: 10.1111/1346-8138.13900
    連結:
  23. Bissonnette R, Luger T, Thaçi D, et al: Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018. doi: 10.1111/jdv. doi: 10.1111/jdv.14878
    連結:
  24. Egeberg A, Ottosen MB, Gniadecki R, et al: Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018;178:509-19. doi: 10.1111/bjd.16102
    連結:
  25. Kammüller M, Tsai TF, Griffiths CE, et al: Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol 2017;6:e152. doi: 10.1038/cti.2017.34
    連結:
  26. Papp KA, Leonardi CL, Blauvelt A, et al: Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol 2018;178:674-81. doi: 10.1111/bjd.16050
    連結:
  27. Reich K, Pinter A, Lacour JP, et al: Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol 2017;177:1014-23. doi: 10.1111/bjd.15666
    連結:
  28. Lebwohl MG, Papp KA, Marangell LB, et al: Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol 2018;78:81-9. doi: 10.1016/j.jaad.2017.08.024
    連結:
  29. Blauvelt A, Papp KA, Griffiths CE, et al: Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017;76:405-17. doi: 10.1016/j.jaad.2016.11.041
    連結:
  30. Reich K, Armstrong AW, Foley P, et al: Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trials. J Am Acad Dermatol 2017;76:418-31. doi: 10.1016/j.jaad.2016.11.042
    連結:
  31. Langley RG, Tsai TF, Flavin S, et al: Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 2018;178:114-23. doi: 10.1111/bjd.15750
    連結:
  32. Simpson EL, Bieber T, Guttman-Yassky E, et al: Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016;375:2335-48. doi: 10.1056/NEJMoa1610020
    連結:
  33. Blauvelt A, de Bruin-Weller M, Gooderham M, et al: Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389:2287-303. doi: 10.1016/S0140-6736(17)31191-1
    連結:
  34. de Bruin-Weller M, Thaçi D, Smith CH, et al: Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2017 Nov 28. doi: 10.1111/bjd.16156. [Epub ahead of print]
    連結:
  35. Kimball AB, Okun MM, Williams DA, et al: Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016;375:422-34. doi: 10.1056/NEJMoa1504370
    連結:
  36. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al: First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017;389:2031-40. doi: 10.1016/S0140-6736(17)30070-3
    連結:
  37. Zhu X, Zheng M, Song M, et al: Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol 2013;12:166-74.
  38. Langley RG, Papp K, Gottlieb AB, et al: Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2013;27:1252-61.